Autolus Therapeutics (NASDAQ:AUTL) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Autolus Therapeutics (NASDAQ:AUTLGet Rating) announced its quarterly earnings data on Thursday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04), Fidelity Earnings reports. Autolus Therapeutics had a negative net margin of 6,551.06% and a negative return on equity of 56.00%. During the same quarter in the prior year, the company earned ($0.47) EPS.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL traded up $0.23 on Friday, reaching $3.48. The company’s stock had a trading volume of 206,125 shares, compared to its average volume of 113,315. Autolus Therapeutics has a 52-week low of $1.96 and a 52-week high of $7.90. The company has a 50-day simple moving average of $2.73 and a 200 day simple moving average of $3.41.

Hedge Funds Weigh In On Autolus Therapeutics

Large investors have recently made changes to their positions in the company. Nantahala Capital Management LLC raised its holdings in shares of Autolus Therapeutics by 6.6% in the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company’s stock valued at $18,124,000 after purchasing an additional 268,818 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Autolus Therapeutics by 144.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 375,514 shares of the company’s stock valued at $1,566,000 after purchasing an additional 222,093 shares in the last quarter. UBS Group AG raised its holdings in shares of Autolus Therapeutics by 716.1% in the 1st quarter. UBS Group AG now owns 73,858 shares of the company’s stock valued at $308,000 after purchasing an additional 64,808 shares in the last quarter. Finally, Cetera Investment Advisers raised its stake in shares of Autolus Therapeutics by 8.3% during the 1st quarter. Cetera Investment Advisers now owns 124,300 shares of the company’s stock worth $518,000 after acquiring an additional 9,550 shares in the last quarter. 61.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Truist Financial reduced their price target on shares of Autolus Therapeutics from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, June 14th. Needham & Company LLC dropped their price objective on shares of Autolus Therapeutics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday.

About Autolus Therapeutics

(Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Further Reading

Earnings History for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.